Correction: *Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19*

Ascierto PA, Fox B, Urba W, *et al*. Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19. *J Immunother Cancer*. 2020;8:e000878. doi: 10.1136/jitc-2020-000878

Since the online publication of this article, the authors have noticed the following errors:

1) The following authors were missing the middle initial in their name; Bernard A Fox, Walter J Urba, Julie R Brahmer, Daniel S Chen, Tanja D de Gruijl, F Stephen Hodi Jr, Howard L Kaufman, Michael T Lotze, Kim M Margolin, Francesco M Marincola. The author name Jon M Wigginton was also spelt incorrectly as Jon M Wiggington. The author list is shown below and has been updated in the article.

Paolo Antonio Ascierto,[1] Bernard A Fox,[2] Walter J Urba,[2] Ana Carrizosa Anderson,[3] Michael B Atkins,[4] Ernest C Borden,[5] Julie R Brahmer,[6] Lisa H Butterfield,[7] Alessandra Cesano,[8] Daniel S Chen,[9] Tanja D de Gruijl,[10] Robert O Dillman,[11] Charles G Drake,[12] Leisha A Emens,[13] Thomas F Gajewski,[14] James L Gulley,[15] F Stephen Hodi Jr,[16] Patrick Hwu,[17] David Kaufman,[18] Howard L Kaufman,[19] Michael T Lotze,[20] Douglas G McNeel,[21] Kim A Margolin,[22] Francesco M Marincola,[23] Michael J Mastrangelo,[24] Marcela V Maus,[25] David R Parkinson,[26] Pedro J Romero,[27] Paul M Sondel,[28] Stefani Spranger,[29] Mario Sznol,[30] George J Weiner,[31] Jon M Wigginton,[32] Jeffrey S Weber[33]

2) Affiliations 1, 2, 3, 4, 5, 11, 14, 15, 16, 20, 21, 22, 26, 28 were incorrect and affiliations 8, 32, 34 have been removed. The updated affiliation list is shown below and has been updated in the article.

[1]Istituto Nazionale Tumori IRCCS Fondazione 'G. Pascale', Naples, Italy
[2]Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, Oregon, USA
[3]Harvard Medical School, Boston, Massachusetts, USA
[4]Georgetown Lombardi Comprehensive Cancer Center, Washington DC, USA
[5]University of Wisconsin Clinical Cancer Center, Madison, Wisconsin, USA
[6]Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA
[7]Research, Parker Institute for Cancer Immunotherapy, San Francisco, California, USA
[8]ESSA Pharma Inc, Redwood City, California, USA
[9]IGM Biosciences Inc, Mountain View, California, USA
[10]Medical Oncology - Amsterdam University Medical Centers, Vrije Universiteit-Cancer Center Amsterdam, Amsterdam, The Netherlands
[11]AIVITA Biomedical, Inc, Irvine, California, USA
[12]Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York, USA
[13]UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA
[14]Pathology and Medicine, Immunology and Cancer Program, University of Chicago, Chicago, Illinois, USA
[15]National Cancer Institute, Bethesda, Maryland, USA
[16]Dana Farber Cancer Institute, Boston, Massachusetts, USA
[17]University of Texas MD Anderson Cancer Center, Houston, Texas, USA
[18]Bill & Melinda Gates Medical Research Institute, Cambridge, Massachusetts, USA
[19]Immuneering Corp New York, New York, New York, USA
[20]University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
[21]Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin, USA
[22]Medical Oncology, City of Hope National Medical Center, Duarte, California, USA
[23]Refuge Biotechnologies, Menlo Park, California, USA
[24]Thomas Jefferson Medical College, Philadelphia, Pennsylvania, USA
[25]Massachusetts General Hospital Cancer Center, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, USA

[26]ESSA Pharma Inc, Palo Alto, California, USA
[27]Oncology, University of Lausanne, Lausanne, VD, Switzerland
[28]Pediatrics, University of Wisconsin Madison, Madison, Wisconsin, USA
[29]Massachusetts Institute of Technology Koch Institute for Integrative Cancer Research, Cambridge, Massachusetts, USA
[30]Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut, USA
[31]Holden Comprehensive Cancer Center, The University of Iowa, Iowa City, Iowa, USA
[32]MacroGenics Inc, Rockville, Maryland, USA
[33]Laura and Isaac Perlmutter Comprehensive Cancer Center, NYU Langone Medical Center, New York, New York, USA

3) In the main text,

- The sentence 'The hypoxia and profound inflammatory response associated with the pneumonitis observed with the severe acute respiratory virus coronavirus-2 SARS-COV-2 virus…' now reads 'The hypoxia and profound inflammatory response associated with the pneumonitis observed with the SARS-CoV-2 virus…'
- The sentence 'One possibility is to encourage the use of IL-6 or IL-6-receptor (IL-6R) blocking antibodies like tocilizumab (Actemra, Roche-Genentech), sarilumab (Kevzara, Regeneron) and siltuximab (Sylvant, EUSA Pharma)…' now reads 'One possibility is to encourage the use of IL-6 or IL-6-receptor (IL-6R) blocking antibodies like tocilizumab (Actemra™, Roche-Genentech), sarilumab (Kevzara™, Regeneron) and siltuximab (Sylvant™, EUSA Pharma)…'
- The sentence '…including tocilizumab and sarilumab for use on a compassionate basis to critically ill hospitalized COVID-19-infected patients during this extraordinary situation' now reads '…including tocilizumab and sarilumab for use on a compassionate basis to critically ill hospitalized SARS-CoV-2-infected patients during this extraordinary situation'

4) To acknowledge medical writing support, the acknowledgment section has been updated to read:

'The authors thank the clinicians working tirelessly on the frontlines of the COVID-19 pandemic. The authors also acknowledge SITC staff for their contributions including Sam Million Weaver, PhD for medical writing and editorial support and Angela Kilbert for project management and assistance. Additionally, the authors wish to thank the society for supporting the manuscript development.'

5) In the competing interests section:

- Bristol-Myers Squibb was spelt incorrectly as 'Bristol-Myer Squibb' and 'Bristol-Myers-Squibb'
- The initials for authors BF, JB, ACA, DC, TdG. HK, ML, FM, KM now read BAF, JRB, AC, DSC, TDG, HLK, MTL, FMM, KAM

J Immunother Cancer 2020;**13**:e000878corr1. doi:10.1136/jitc-2020-000878corr1

Amendment to *'Correction: Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19'*

Correction: Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19. *J Immunother Cancer* 2020;**8:**e000878corr1. doi: 10.1136/jitc-2020-000878corr1

This correction notice incorrectly stated that Kim Margolin's middle initial was 'M' instead of 'A' in the first paragraph.

The first paragraph should instead read, 'The following authors were missing the middle initials in their names; Bernard A Fox, Walter J Urba, Julie R Brahmer, Daniel S Chen, Tanja D de Gruijl, F Stephen Hodi Jr, Howard L Kaufman, Michael T Lotze, Kim A Margolin, Francesco M Marincola. The author name Jon M Wigginton was also spelt incorrectly as Jon M Wiggington. The author list is shown below and has been updated in the article.'

Paolo Antonio Ascierto, Bernard A Fox, Walter J Urba, Ana Carrizosa Anderson, Michael B Atkins, Ernest C Borden, Julie R Brahmer, Lisa H Butterfield, Alessandra Cesano, Daniel S Chen, Tanja D de Gruijl, Robert O Dillman, Charles G Drake, Leisha A Emens, Thomas F Gajewski, James L Gulley, F Stephen Hodi Jr, Patrick Hwu, David Kaufman, Howard L Kaufman, Michael T Lotze, Douglas G McNeel, Kim A Margolin, Francesco M Marincola, Michael J Mastrangelo, Marcela V Maus, David R Parkinson, Pedro J Romero, Paul M Sondel, Stefani Spranger, Mario Sznol, George J Weiner, Jon M Wigginton and Jeffrey S Weber

J Immunother Cancer 2020;**8**:e000878corr1Amendment. doi:10.1136/jitc-2020-000878corr1Amendment